Pharmafile Logo

Article

August 2, 2021 | Alzheimer's 

A glimmer of hope for Alzheimer’s patients, but at what cost?

In her latest article for PME Magazine, Rachel Howard explores the implications for P&R decisions in EU countries following the FDA’s recent approval of Aduhelm as a treatment for Alzheimer’s disease.

Read the full article here: https://bit.ly/3ikje2A

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Infographic: Spondyloarthritis

Overview of spondyloarthritis patient profiles and treatment pathways.

Webinar: Demand assessment – Reflecting real world choices

How study design which reflects doctors’ real world choices can optimise results.

Evaluating the potential of a pre-launch prodct in a real-life setting

Using in-depth-interviews as well as a SmartPhone app to collect real patient cases from physicians to find out opportunity for a new product.

Competition from within

Published in eyeforpharma July 29 by Rachel Howard

Infographic: RA Perceptions

HCPs predict the future of the biologics market

From chaos to calm: how to make sense of social media

What do you know about chaos theory?

Breaking Down the Barriers to Effective Treatment of Hepatitis C in Latin America

Published in eyeforpharma June 9 by Rachel Howard and Raquel Nunez.

Infographic: HCV LATAM

An introduction to the HCV LATAM patient.

Spotlight on Saudi Arabia

Published in eyeforpharma 20 May by Rachel Howard